Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 380

1.

Corrigendum: Rheumatoid Synovial Fluids Regulate the Immunomodulatory Potential of Adipose-Derived Mesenchymal Stem Cells Through a TNF/NF-κB-Dependent Mechanism.

Sayegh S, El Atat O, Diallo K, Rauwel B, Degboé Y, Cavaignac E, Constantin A, Cantagrel A, Trak-Smayra V, Alaaeddine N, Davignon JL.

Front Immunol. 2019 Aug 20;10:1961. doi: 10.3389/fimmu.2019.01961. eCollection 2019.

2.

Rheumatoid Synovial Fluids Regulate the Immunomodulatory Potential of Adipose-Derived Mesenchymal Stem Cells Through a TNF/NF-κB-Dependent Mechanism.

Sayegh S, El Atat O, Diallo K, Rauwel B, Degboé Y, Cavaignac E, Constantin A, Cantagrel A, Trak-Smayra V, Alaaeddine N, Davignon JL.

Front Immunol. 2019 Jun 28;10:1482. doi: 10.3389/fimmu.2019.01482. eCollection 2019. Erratum in: Front Immunol. 2019 Aug 20;10:1961.

3.

Osteoclast-Derived Autotaxin, a Distinguishing Factor for Inflammatory Bone Loss.

Flammier S, Peyruchaud O, Bourguillault F, Duboeuf F, Davignon JL, Norman DD, Isaac S, Marotte H, Tigyi G, Machuca-Gayet I, Coury F.

Arthritis Rheumatol. 2019 Jun 4. doi: 10.1002/art.41005. [Epub ahead of print]

PMID:
31162832
4.

Polarization of Rheumatoid Macrophages by TNF Targeting Through an IL-10/STAT3 Mechanism.

Degboé Y, Rauwel B, Baron M, Boyer JF, Ruyssen-Witrand A, Constantin A, Davignon JL.

Front Immunol. 2019 Jan 18;10:3. doi: 10.3389/fimmu.2019.00003. eCollection 2019.

5.

Modulation of T-cell responses by anti-tumor necrosis factor treatments in rheumatoid arthritis: a review.

Davignon JL, Rauwel B, Degboé Y, Constantin A, Boyer JF, Kruglov A, Cantagrel A.

Arthritis Res Ther. 2018 Oct 12;20(1):229. doi: 10.1186/s13075-018-1725-6. Review.

6.

Bone degradation machinery of osteoclasts: An HIV-1 target that contributes to bone loss.

Raynaud-Messina B, Bracq L, Dupont M, Souriant S, Usmani SM, Proag A, Pingris K, Soldan V, Thibault C, Capilla F, Al Saati T, Gennero I, Jurdic P, Jolicoeur P, Davignon JL, Mempel TR, Benichou S, Maridonneau-Parini I, Vérollet C.

Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):E2556-E2565. doi: 10.1073/pnas.1713370115. Epub 2018 Feb 20.

7.

Three-Dimensional Directionality Is a Pivotal Structural Feature for the Bioactivity of Azabisphosphonate-Capped Poly(PhosphorHydrazone) Nanodrug Dendrimers.

Hayder M, Garzoni M, Bochicchio D, Caminade AM, Couderc F, Ong-Meang V, Davignon JL, Turrin CO, Pavan GM, Poupot R.

Biomacromolecules. 2018 Mar 12;19(3):712-720. doi: 10.1021/acs.biomac.7b01398. Epub 2018 Feb 26.

PMID:
29443507
8.
9.

WAT apoC-I secretion: role in delayed chylomicron clearance in vivo and ex vivo in WAT in obese subjects.

Cyr Y, Wassef H, Bissonnette S, Lamantia V, Davignon J, Faraj M.

J Lipid Res. 2016 Jun;57(6):1074-85. doi: 10.1194/jlr.P064170. Epub 2016 Apr 3.

10.

Treat-to-target versus dose-adapted statin treatment of cholesterol to reduce cardiovascular risk.

Müller-Wieland D, Assmann G, Carmena R, Davignon J, von Eckardstein A, Farinaro E, Greten H, Olsson AG, Riesen WF, Shlyakhto E.

Eur J Prev Cardiol. 2016 Feb;23(3):275-81. doi: 10.1177/2047487314567001. Epub 2015 Jan 16.

PMID:
25595550
11.

Anti-TNF certolizumab pegol induces antioxidant response in human monocytes via reverse signaling.

Boyer JF, Baron M, Constantin A, Degboé Y, Cantagrel A, Davignon JL.

Arthritis Res Ther. 2016 Mar 1;18:56. doi: 10.1186/s13075-016-0955-8.

12.

Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib.

Charles-Schoeman C, Fleischmann R, Davignon J, Schwartz H, Turner SM, Beysen C, Milad M, Hellerstein MK, Luo Z, Kaplan IV, Riese R, Zuckerman A, McInnes IB.

Arthritis Rheumatol. 2015 Mar;67(3):616-25. doi: 10.1002/art.38974.

13.

PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism.

Bridge SH, Sheridan DA, Felmlee DJ, Crossey MM, Fenwick FI, Lanyon CV, Dubuc G, Seidah NG, Davignon J, Thomas HC, Taylor-Robinson SD, Toms GL, Neely RD, Bassendine MF.

J Hepatol. 2015 Apr;62(4):763-70. doi: 10.1016/j.jhep.2014.11.016. Epub 2014 Nov 21.

PMID:
25463543
14.

Canadian Cardiovascular Society position statement on familial hypercholesterolemia.

Primary Panel:, Genest J, Hegele RA, Bergeron J, Brophy J, Carpentier A, Couture P, Davignon J, Dufour R, Frohlich J, Gaudet D, Gupta M, Krisnamoorthy P, Mancini J, McCrindle B, Raggi P, Ruel I, St-Pierre J.

Can J Cardiol. 2014 Dec;30(12):1471-81. doi: 10.1016/j.cjca.2014.09.028. Epub 2014 Oct 2. Review.

15.

PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.

Saavedra YG, Dufour R, Davignon J, Baass A.

Arterioscler Thromb Vasc Biol. 2014 Dec;34(12):2700-5. doi: 10.1161/ATVBAHA.114.304406. Epub 2014 Oct 2.

PMID:
25278291
16.

Changes in total and central fat mass after a hypocaloric diet associate with changes of apoC-I in postmenopausal obese women.

Wassef H, Davignon J, Prud'homme D, Rabasa-Lhoret R, Faraj M.

J Clin Lipidol. 2014 Sep-Oct;8(5):510-9. doi: 10.1016/j.jacl.2014.06.004. Epub 2014 Jun 17.

PMID:
25234564
17.

Clearance of plasma proprotein convertase subtilisin/kexin 9 by low-density lipoprotein apheresis.

Duell PB, Dubuc G, Seidah NG, Davignon J.

Circ Res. 2014 Jun 20;115(1):e3-4. doi: 10.1161/CIRCRESAHA.114.304163. No abstract available.

PMID:
24951769
18.

Modulation of pro-inflammatory activation of monocytes and dendritic cells by aza-bis-phosphonate dendrimer as an experimental therapeutic agent.

Degboé Y, Fruchon S, Baron M, Nigon D, Turrin CO, Caminade AM, Poupot R, Cantagrel A, Davignon JL.

Arthritis Res Ther. 2014 Apr 18;16(2):R98. doi: 10.1186/ar4546.

19.

The effect of insulin on circulating PCSK9 in postmenopausal obese women.

Awan Z, Dubuc G, Faraj M, Dufour R, Seidah NG, Davignon J, Rabasa-Lhoret R, Baass A.

Clin Biochem. 2014 Aug;47(12):1033-9. doi: 10.1016/j.clinbiochem.2014.03.022. Epub 2014 Apr 8.

PMID:
24721682
20.

Residual macrovascular risk in 2013: what have we learned?

Fruchart JC, Davignon J, Hermans MP, Al-Rubeaan K, Amarenco P, Assmann G, Barter P, Betteridge J, Bruckert E, Cuevas A, Farnier M, Ferrannini E, Fioretto P, Genest J, Ginsberg HN, Gotto AM Jr, Hu D, Kadowaki T, Kodama T, Krempf M, Matsuzawa Y, Núñez-Cortés JM, Monfil CC, Ogawa H, Plutzky J, Rader DJ, Sadikot S, Santos RD, Shlyakhto E, Sritara P, Sy R, Tall A, Tan CE, Tokgözoğlu L, Toth PP, Valensi P, Wanner C, Zambon A, Zhu J, Zimmet P; Residual Risk Reduction Initiative (R3i).

Cardiovasc Diabetol. 2014 Jan 24;13:26. doi: 10.1186/1475-2840-13-26. Review.

21.

An azabisphosphonate-capped poly(phosphorhydrazone) dendrimer for the treatment of endotoxin-induced uveitis.

Fruchon S, Caminade AM, Abadie C, Davignon JL, Combette JM, Turrin CO, Poupot R.

Molecules. 2013 Aug 5;18(8):9305-16. doi: 10.3390/molecules18089305.

22.

The role of potatoes and potato components in cardiometabolic health: a review.

McGill CR, Kurilich AC, Davignon J.

Ann Med. 2013 Nov;45(7):467-73. doi: 10.3109/07853890.2013.813633. Epub 2013 Jul 15. Review.

PMID:
23855880
23.

Regional distribution and metabolic effect of PCSK9 insLEU and R46L gene mutations and apoE genotype.

Awan Z, Delvin EE, Levy E, Genest J, Davignon J, Seidah NG, Baass A.

Can J Cardiol. 2013 Aug;29(8):927-33. doi: 10.1016/j.cjca.2013.03.004. Epub 2013 Jun 3.

PMID:
23743349
24.

Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations.

Mayne J, Ooi TC, Raymond A, Cousins M, Bernier L, Dewpura T, Sirois F, Mbikay M, Davignon J, Chrétien M.

Lipids Health Dis. 2013 May 10;12:70. doi: 10.1186/1476-511X-12-70.

25.

Targeting monocytes/macrophages in the treatment of rheumatoid arthritis.

Davignon JL, Hayder M, Baron M, Boyer JF, Constantin A, Apparailly F, Poupot R, Cantagrel A.

Rheumatology (Oxford). 2013 Apr;52(4):590-8. doi: 10.1093/rheumatology/kes304. Epub 2012 Nov 30. Review.

PMID:
23204551
26.

Egg yolk consumption, smoking and carotid plaque: reply to letters to the Editor by Sean Lucan and T Dylan Olver et al.

Spence JD, Jenkins DJ, Davignon J.

Atherosclerosis. 2013 Mar;227(1):189-91. doi: 10.1016/j.atherosclerosis.2012.10.075. Epub 2012 Nov 8. No abstract available.

PMID:
23177013
27.

White adipose tissue apolipoprotein C-I secretion in relation to delayed plasma clearance of dietary fat in humans.

Wassef H, Salem H, Bissonnette S, Baass A, Dufour R, Davignon J, Faraj M.

Arterioscler Thromb Vasc Biol. 2012 Nov;32(11):2785-93. doi: 10.1161/ATVBAHA.112.300306. Epub 2012 Sep 20.

PMID:
22995522
28.

Egg yolk consumption and carotid plaque.

Spence JD, Jenkins DJ, Davignon J.

Atherosclerosis. 2012 Oct;224(2):469-73. doi: 10.1016/j.atherosclerosis.2012.07.032. Epub 2012 Aug 1.

PMID:
22882905
29.

Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation.

Seidah NG, Poirier S, Denis M, Parker R, Miao B, Mapelli C, Prat A, Wassef H, Davignon J, Hajjar KA, Mayer G.

PLoS One. 2012;7(7):e41865. doi: 10.1371/journal.pone.0041865. Epub 2012 Jul 27.

30.

Link between traditional cardiovascular risk factors and inflammation in patients with early arthritis: results from a French multicenter cohort.

Boyer JF, Bongard V, Cantagrel A, Jamard B, Gottenberg JE, Mariette X, Davignon JL, Ferrières J, Ruidavets JB, Dallongeville J, Arveiler D, Cambon-Thomsen A, Constantin A.

Arthritis Care Res (Hoboken). 2012 Jun;64(6):872-80. doi: 10.1002/acr.21623. Epub 2012 Jan 24.

31.

Pleiotropic effects of pitavastatin.

Davignon J.

Br J Clin Pharmacol. 2012 Apr;73(4):518-35. doi: 10.1111/j.1365-2125.2011.04139.x. Review.

32.

Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture.

Mayne J, Dewpura T, Raymond A, Bernier L, Cousins M, Ooi TC, Davignon J, Seidah NG, Mbikay M, Chrétien M.

Clin Chem. 2011 Oct;57(10):1415-23. doi: 10.1373/clinchem.2011.165191. Epub 2011 Aug 3.

33.

Novel model of placental tissue explants infected by cytomegalovirus reveals different permissiveness in early and term placentae and inhibition of indoleamine 2,3-dioxygenase activity.

Lopez H, Benard M, Saint-Aubert E, Baron M, Martin H, Al Saati T, Plantavid M, Duga-Neulat I, Berrebi A, Cristini C, Arnaud C, Davrinche C, Davignon JL, Casper C.

Placenta. 2011 Jul;32(7):522-30. doi: 10.1016/j.placenta.2011.04.016. Epub 2011 May 24.

PMID:
21605903
34.

A phosphorus-based dendrimer targets inflammation and osteoclastogenesis in experimental arthritis.

Hayder M, Poupot M, Baron M, Nigon D, Turrin CO, Caminade AM, Majoral JP, Eisenberg RA, Fournié JJ, Cantagrel A, Poupot R, Davignon JL.

Sci Transl Med. 2011 May 4;3(81):81ra35. doi: 10.1126/scitranslmed.3002212.

35.

Cytosolic phospholipase A2α gene silencing in the myeloid lineage alters development of Th1 responses and reduces disease severity in collagen-induced arthritis.

Courties G, Baron M, Presumey J, Escriou V, van Lent P, Scherman D, Cantagrel A, van den Berg WB, Jorgensen C, Apparailly F, Davignon JL.

Arthritis Rheum. 2011 Mar;63(3):681-90. doi: 10.1002/art.30174.

36.

Dietary cholesterol and egg yolks: not for patients at risk of vascular disease.

Spence JD, Jenkins DJ, Davignon J.

Can J Cardiol. 2010 Nov;26(9):e336-9. Review.

37.

Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis.

Boyer JF, Gourraud PA, Cantagrel A, Davignon JL, Constantin A.

Joint Bone Spine. 2011 Mar;78(2):179-83. doi: 10.1016/j.jbspin.2010.07.016. Epub 2010 Sep 17. Review.

PMID:
20851020
38.

Maintenance of cytomegalovirus-specific CD4pos T-cell response in rheumatoid arthritis patients receiving anti-tumor necrosis factor treatments.

Davignon JL, Boyer JF, Jamard B, Nigon D, Constantin A, Cantagrel A.

Arthritis Res Ther. 2010;12(4):R142. doi: 10.1186/ar3083. Epub 2010 Jul 15.

39.

The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis.

Davignon J, Dubuc G, Seidah NG.

Curr Atheroscler Rep. 2010 Sep;12(5):308-15. doi: 10.1007/s11883-010-0123-6. Review.

PMID:
20623344
40.

Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels.

Grover SA, Kaouache M, Joseph L, Barter P, Davignon J.

Arch Intern Med. 2009 Oct 26;169(19):1775-80. doi: 10.1001/archinternmed.2009.328.

PMID:
19858435
41.
42.

Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents.

Baass A, Dubuc G, Tremblay M, Delvin EE, O'Loughlin J, Levy E, Davignon J, Lambert M.

Clin Chem. 2009 Sep;55(9):1637-45. doi: 10.1373/clinchem.2009.126987. Epub 2009 Jul 23.

43.

A new method for measurement of total plasma PCSK9: clinical applications.

Dubuc G, Tremblay M, Paré G, Jacques H, Hamelin J, Benjannet S, Boulet L, Genest J, Bernier L, Seidah NG, Davignon J.

J Lipid Res. 2010 Jan;51(1):140-9. doi: 10.1194/jlr.M900273-JLR200.

44.

Characterization of a new LCAT mutation causing familial LCAT deficiency (FLD) and the role of APOE as a modifier gene of the FLD phenotype.

Baass A, Wassef H, Tremblay M, Bernier L, Dufour R, Davignon J.

Atherosclerosis. 2009 Dec;207(2):452-7. doi: 10.1016/j.atherosclerosis.2009.05.014. Epub 2009 May 21.

PMID:
19515369
45.

Apolipoprotein E limits oxidative stress-induced cell dysfunctions in human adipocytes.

Tarnus E, Wassef H, Carmel JF, Rondeau P, Roche M, Davignon J, Bernier L, Bourdon E.

FEBS Lett. 2009 Jun 18;583(12):2042-8. doi: 10.1016/j.febslet.2009.05.016. Epub 2009 May 18.

46.

Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.

Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, Davignon J; CAP Investigators.

Clin Ther. 2008 Dec;30(12):2298-313. doi: 10.1016/j.clinthera.2008.12.023.

PMID:
19167589
47.

High expression of apolipoprotein E impairs lipid storage and promotes cell proliferation in human adipocytes.

Carmel JF, Tarnus E, Cohn JS, Bourdon E, Davignon J, Bernier L.

J Cell Biochem. 2009 Mar 1;106(4):608-17. doi: 10.1002/jcb.22037.

PMID:
19130493
48.
49.

A PCSK9 variant and familial combined hyperlipidaemia.

Abifadel M, Bernier L, Dubuc G, Nuel G, Rabès JP, Bonneau J, Marques A, Marduel M, Devillers M, Munnich A, Erlich D, Varret M, Roy M, Davignon J, Boileau C.

J Med Genet. 2008 Dec;45(12):780-6. doi: 10.1136/jmg.2008.059980. Epub 2008 Aug 15.

PMID:
18708425
50.

Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.

Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J, Tremblay M, Jacques H, Jin W, Davignon J, Seidah NG, Prat A.

Hepatology. 2008 Aug;48(2):646-54. doi: 10.1002/hep.22354.

PMID:
18666258

Supplemental Content

Loading ...
Support Center